**Supplement 3: Supplemental Tables and Figures**

|  |
| --- |
| **Survey Demographics** |
| **Years in Practice  - Available for 570/668 (85.3%) N(%)** | **N(%)** |
| Less than 10 years | 256 (44.9%) |
| More than 10 years | 181 (31.8%) |
| In Training | 133 (23.3%) |
| **Region - Available for 561/668 (84.0%) N(%)** |  |
| Europe | 187 (33.3%) |
| North America | 156 (23.4%) |
| Asia | 93 (16.6%) |
| Central/South America | 87 (15.5%) |
| Australia | 15 (2.7%) |
| Africa | 10 (1.8%) |

**Supplemental Table 1.** Survey demographics including years in practice and region of practice

|  |
| --- |
| **Interviews** |
| **Age Range –** **N(%)** | **N(%)** |
| 35-44 | 13 (59.1%) |
| 45-54 | 8 (36.4%) |
| 55-64 | 1 (4.6%) |
| **Sex - N(%)** |
| Male | 18 (81.8%) |
| Female | 4 (18.2%) |
| **Practice Location - N (%)\*** |
| Europe | 11 (50.0%) |
| USA/Canada | 9 (40.9%) |
| Asia | 2 (9.1%) |
| Africa | 1 (4.5%) |
| Caribbean | 1 (4.5%) |
| Australia | 1 (4.5%) |
| **Specialty- N (%)\*** |  |
| Neurology  | 11 (50.0%) |
| Interventional neuroradiology | 5 (22.7%) |
| Neurovascular surgery | 3 (13.6%) |
| Geriatrics | 3 (13.6%) |

**Supplemental Table 2**. Interviewee demographics including age, sex and practice location. \*Note practice locations data does not add to 100% as 3 participants practiced in 2 locations, each were included in this table.



Supplemental Figure 1. Themes from the interviews regarding management of the hot carotid with ILT. Organized by region (Panel 1) and Specialty (Panel 2). X-axis values represent the absolute number of responses. ILT (intraluminal thrombus), LMWH (low molecular weight heparin), DAPT (dual antiplatet therapy), CAS (carotid artery stenting), CEA (carotid endarterectomy).



Supplemental Figure 2. Themes from the interviews regarding future trials and uncertainty in the hot carotid with ILT. Organized by region (Panel 1) and Specialty (Panel 2). X-axis values represent the absolute number of responses. ILT (intraluminal thrombus) DAPT (dual antiplatet therapy).



Comparator Arms

Revascularization versus DAPT

Antithrombotic choice

Whom to anticoagulate

Persistent Thrombus

Anticipated Challenges

Revascularization

ILT

Degree of Stenosis

Imaging features

CEA

CEA timing

Anticoagulation versus DAPT

Number of events

Sample Size

Patient Selection

Comorbidities

ILT definition

Inpatient

Management

Surgeon preference

Infarct size

Clot morphology

Happy to randomize

Uncertainty

Acceptable Comparator Groups

Future Trials

Reimaging

ASA for ILT

Procedure Modification

Clot aspiration

Location of clot

Length of ILT

Multi-disciplinary team

Persistent ILT

Holds off on procedure

DSA

Doppler

Imaging for ILT

Procedures

CAS over CEA

Persistent ILT

CEA over CAS

CEA for persistent ILT

Timing of procedure

Oral Anticoagulation

DAPT with ILT

Medical therapy for ILT

Heparin for ILT

LMWH for ILT

Intraluminal Thrombi Management

**Supplemental Figure 3. Coding Treemap.** At the center are the three main topics explored. The areas are sized to reflect the number of coding references in the interviews. A larger area indicates more coding references. ILT (intraluminal thrombus), LMWH (low molecular weight heparin), DAPT (dual antiplatet therapy), CAS (carotid artery stenting), CEA (carotid endarterectomy), DSA (digital subtraction angiography).